Product
Help
Pricing
About
Jobs
Log in
Get started
Author
Add to collection
Lenka Novakova
Observed names:
L Novakova,
L. Novakova,
Novakova L,
Novakova, L,
Novakova, Lenka
Institutions:
Sahlgrenska University Hospital,
Region Västra Götaland,
University of Gothenburg
Observed institutions:
Sahlgrenska University Hospital,
Danderyds sjukhus,
Karolinska Institutet,
Region Västra Götaland,
UCL Queen Square Institute of Neurology,
University College London,
University of Gothenburg,
Umeå University
show all 8
ORCID:
0000-0001-7899-6395
Observed ORCID:
0000-0001-7899-6395
OpenAlex ID:
A5057206152
A multicentre validation study of the diagnostic value of plasma neurofilament light
2021
·
Nicholas J. Ashton
, Shorena Janelidze
, et al.
·
Nature Communications
·
605
PDF
Monitoring disease activity in multiple sclerosis using serum neurofilament light protein
2017
·
Lenka Novakova
, Henrik Zetterberg
, et al.
·
Neurology
·
466
Rituximab in multiple sclerosis: A retrospective observational study on safety and efficacy
2016
·
Jonatan Salzer
, Rasmus Svenningsson
, et al.
·
Neurology
·
392
PDF
Rituximab versus fingolimod after natalizumab in multiple sclerosis patients
2016
·
Peter Alping
, Thomas Frisell
, et al.
·
Annals of Neurology
·
248
PDF
Inflammation-related plasma and CSF biomarkers for multiple sclerosis
2020
·
Jesse Huang
, Mohsen Khademi
, et al.
·
Proceedings of the National Academy of Sciences
·
210
Cerebrospinal fluid biomarkers as a measure of disease activity and treatment efficacy in relapsing‐remitting multiple sclerosis
2016
·
Lenka Novakova
, Markus Axelsson
, et al.
·
Journal of Neurochemistry
·
157
PDF
Cerebrospinal fluid biomarkers of inflammation and degeneration as measures of fingolimod efficacy in multiple sclerosis
2016
·
Lenka Novakova
, Markus Axelsson
, et al.
·
Multiple Sclerosis Journal
·
119
PDF
Soluble TREM-2 in cerebrospinal fluid from patients with multiple sclerosis treated with natalizumab or mitoxantrone
2016
·
Annika Öhrfelt
, Markus Axelsson
, et al.
·
Multiple Sclerosis Journal
·
105
PDF
Kappa free light chain index as a diagnostic biomarker in multiple sclerosis: A real‐world investigation
2021
·
Igal Rosenstein
, Sofia Rasch
, et al.
·
Journal of Neurochemistry
·
67
Autologous haematopoietic stem cell transplantation compared with alemtuzumab for relapsing–remitting multiple sclerosis: an observational study
2020
·
Christina Zhukovsky
, Sofia Sandgren
, et al.
·
Journal of Neurology Neurosurgery & Psychiatry
·
58
PDF
Searching for neurodegeneration in multiple sclerosis at clinical onset: Diagnostic value of biomarkers
2018
·
Lenka Novakova
, Markus Axelsson
, et al.
·
PLoS ONE
·
58
PDF
Intrathecal kappa free light chain synthesis is associated with worse prognosis in relapsing–remitting multiple sclerosis
2023
·
Igal Rosenstein
, Markus Axelsson
, et al.
·
Journal of Neurology
·
57
PDF
Natalizumab, rituximab and fingolimod as escalation therapy in multiple sclerosis
2019
·
M. Boremalm
, A. Juto
, et al.
·
European Journal of Neurology
·
42
Association of serum glial fibrillary acidic protein with progression independent of relapse activity in multiple sclerosis
2024
·
Igal Rosenstein
, Anna Nordin
, et al.
·
Journal of Neurology
·
35
PDF
NFL and CXCL13 may reveal disease activity in clinically and radiologically stable MS
2020
·
L. Novakova
, M. Axelsson
, et al.
·
Multiple Sclerosis and Related Disorders
·
35
PDF
Reduced cerebrospinal fluid concentrations of oxysterols in response to natalizumab treatment of relapsing remitting multiple sclerosis
2015
·
Lenka Novakova
, Markus Axelsson
, et al.
·
Journal of the Neurological Sciences
·
30
Exploring CSF neurofilament light as a biomarker for MS in clinical practice; a retrospective registry-based study
2021
·
Igal Rosenstein
, Markus Axelsson
, et al.
·
Multiple Sclerosis Journal
·
29
PDF
High levels of kappa free light chain synthesis predict cognitive decline in relapsing-remitting multiple sclerosis
2023
·
Igal Rosenstein
, Markus Axelsson
, et al.
·
Frontiers in Immunology
·
25
PDF
Diffusion tensor imaging in multiple sclerosis at different final outcomes
2017
·
O. Andersen
, A. Hildeman
, et al.
·
Acta Neurologica Scandinavica
·
24
PDF
High Interferon-γ Uniquely in Vδ1 T Cells Correlates with Markers of Inflammation and Axonal Damage in Early Multiple Sclerosis
2017
·
Avadhesh Kumar Singh
, Lenka Novakova
, et al.
·
Frontiers in Immunology
·
24
PDF
Clinically isolated syndromes with no further disease activity suggestive of multiple sclerosis at the age of population life expectancy
2013
·
L Novakova
, B Skoog
, et al.
·
Multiple Sclerosis Journal
·
22
Serum neurofilament light for detecting disease activity in individual patients in multiple sclerosis: A 48-week prospective single-center study
2024
·
M Johnsson
, YT Stenberg
, et al.
·
Multiple Sclerosis Journal
·
20
Sulfatide isoform pattern in cerebrospinal fluid discriminates progressive MS from relapsing‐remitting MS
2018
·
Lenka Novakova
, Avadhesh Kumar Singh
, et al.
·
Journal of Neurochemistry
·
19
Neurofilament light chain as a diagnostic and prognostic biomarker in Guillain–Barré syndrome
2024
·
Brynhildur Hafsteinsdóttir
, Helen Farman
, et al.
·
Journal of Neurology
·
18
PDF
A five-year observational prospective mono-center study of the efficacy of alemtuzumab in a real-world cohort of patients with multiple sclerosis
2023
·
Sofia Sandgren
, Lenka Novakova
, et al.
·
Frontiers in Neurology
·
17
Show more works
View as search
Works count:
63
Citation count:
3,023
H-index:
21
I10-index:
29
Year
Topic
Type